{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"23andMe Holding Co."},"Symbol":{"label":"Symbol","value":"ME"},"Address":{"label":"Address","value":"349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 938-6300"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"23andMe is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. More than 80% of 23andMe customers voluntarily elect to share their de-identified genetic data with the company, which is used to develop future reports. In 2018, GlaxoSmithKline made an equity investment in the company, entering a five-year collaborative agreement with 23andMe to develop drug candidates."},"CompanyUrl":{"label":"Company Url","value":"https://www.23andme.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Anne E. Wojcicki","title":"Chairman, President & Chief Executive Officer"},{"name":"David Baker","title":"Chief Security Officer & VP-Engineering"},{"name":"Eli Fry","title":"Vice President-Operations"},{"name":"Joseph R. Arron","title":"Chief Scientific Officer"},{"name":"Joyce Tung","title":"Vice President-Research"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}